Global Markets Direct’s, ''Breast Cancer Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, comp...
|
$ 2500
|
|
|
MediPoint: Predictive Breast Cancer Gene Testing - Current and Future Players
Summary
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the i
|
$ 3500
|
|
|
MediPoint: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts
Summary
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to
|
$ 4450
|
|
|
MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts
Summary
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to
|
$ 4450
|
|
|
MediPoint: Predictive Breast Cancer Gene Testing - APAC Analysis and Market Forecasts
Summary
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due
|
$ 4450
|
|
|
MediPoint: Predictive Breast Cancer Gene Testing - South America Analysis and Market Forecasts
Summary
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increa
|
$ 4450
|
|
|
Metastatic Breast Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Metastatic Breast Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the t
|
$ 2500
|
|
|
Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations. New market entrants must possess drug profiles and a savvy clinical development program to overcome such barriers to en...
|
$ 3400
|
|
|
Breast Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Breast Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development
|
$ 2500
|
|
|
China's demand for Breast Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment...
|
$ 4000
|
|
|
TechNavio''s analysts forecast the Global Breast Cancer Drugs market to grow at a CAGR of 1.7 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of breast cancer worldw...
|
$ 1500
|
|
|
The treatment of HER2-negative/hormone receptor-positive breast cancer consists largely of genericized cytotoxic and antihormonal therapies. Avastin (bevacizumab) is currently the only targeted therapy used in this patient population. Patent expir...
|
$ 11400
|
|
|
REPORT HIGHLIGHTSThe global market for Predictive Breast Cancer diagnostic and drug Technologies was valued at $23.4 billion in 2010 and came down to $21.2 billion in 2011. This market is expected to rise at a compound...
|
$ 5450
|
|
|
Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations. New market entrants must possess drug profiles and a savvy clinical development program to overcome such barriers to en...
|
$ 3400
|
|
|
This report provides understanding and access to the breast cancer partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in breast cancer partnering dealsTop breast cancer deals by valu...
|
$ 1695
|
|
|
GlobalData’s pharmaceuticals report, Trastuzumab-DM1 (Breast Cancer) – Analysis and Forecasts to 2020” provides Trastuzumab-DM1 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of ...
|
$ 2000
|
|
|
Report SummaryGlobalData, the industry analysis specialist, has released its new report, Breast Cancer - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of informat...
|
$ 6995
|
|
|
GlobalData’s pharmaceuticals report, Abraxane (Breast Cancer) – Analysis and Forecasts to 2020” provides Abraxane sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, fact...
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Ellence (Breast cancer) - Analysis and Forecasts to 2020” provides Ellence sales forecasts for US, EU5 and Japan. In addition,
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Halaven (Breast cancer) - Analysis and Forecasts to 2020” provides Halaven sales forecasts for US, EU5 and Japan. In addition,
|
$ 2000
|
|
|